搜索
Repligen Corp
RGEN添加自选
134.120USD
-2.880-2.10%
交易中 （美东）报价延迟15分钟
7.55B总市值
146.83市盈率 TTM
关键数据
137.770今开
138.850最高
87.39K成交量
146.83市盈率 TTM
51.37市盈率动
--股息TTM
0.16%换手率
137.000昨收
134.010最低
8.53M成交额
亏损市盈率静
3.59市净率
0.00%股息率 TTM
1.78%ROA
175.77052周最高
0.33量比
-25.51M净利润
56.33M总股本
0.9135每股收益TTM
1.09Beta
2.51%ROE
100.99052周最低
3.53%振幅
55.74%毛利率
7.55B总市值
3.82回报/风险
2.75%风险率
TradingKey Repligen Corp股票评分
单位: USD 更新时间: 2026-06-29操作建议
Repligen Corp当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在医疗设备与耗材行业排名28/204位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价177.75。中期看，股价处于上升通道。近一个月，市场表现较强，技术面和基本面综合得分较高，较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Repligen Corp评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看好
Repligen Corp亮点
亮点风险
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
业绩高增长
公司营业收入稳步增长，连续3年增长16.75%
利润高增长
公司净利润处于行业前列，最新年度总收入738.26M美元
业绩转盈
公司业绩转盈，最新年度盈利美元
估值高估
公司最新PE估值149.98，处于3年历史高位
机构减仓
最新机构持股65.93M股，环比减少3.85%
李·安斯利持仓
明星投资者李·安斯利持仓，最新持仓市值1.58M
分析师目标
根据
22
位分析师
买入
评级
177.749
目标均价
+20.91%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Repligen Corp新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Repligen Corp简介
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
公司代码RGEN
公司Repligen Corp
CEOLoeillot (Olivier)
网址https://www.repligen.com/
相关品种
-0.64%
-1.86%
-1.44%
-1.02%
-1.45%
-0.43%
-4.46%
-2.04%
-1.78%
-0.38%
-0.40%
-1.90%
-0.86%
-1.01%
+1.47%
-3.16%
-2.57%
-1.78%
-1.47%
-0.83%热门品种
常见问题
Repligen Corp(RGEN)的当前股价是多少？
Repligen Corp(RGEN)的当前股价是 137.00。
Repligen Corp的股票代码是什么？
Repligen Corp的股票代码是RGEN。
Repligen Corp股票的52周最高点是多少？
Repligen Corp股票的52周最高点是175.77。
Repligen Corp股票的52周最低点是多少？
Repligen Corp股票的52周最低点是100.99。
Repligen Corp的市值是多少？
Repligen Corp的市值是7.73B。
现在Repligen Corp(RGEN)的股票是买入、持有还是卖出？
根据分析师评级，Repligen Corp(RGEN)的总体评级为买入，目标价格为177.75。
Repligen Corp(RGEN)股票的每股收益（EPS TTM）是多少
Repligen Corp(RGEN)股票的每股收益（EPS TTM）是0.87。
